Furthermore, specific genetic mutations such as MYD88, CD79B, and PIM1 were also associated with higher TMB levels, which suggests that TMB is a potential predictor of survival and prognosis in DLBCL patients (Chen et al., 2021). Here, MYD88 is linked to diffuse large B-cell lymphoma.